High Cutoff Versus High-Flux Haemodialysis for Myeloma Cast Nephropathy in Patients Receiving Bortezomib-Based Chemotherapy (EuLITE): A Phase 2 Randomised Controlled Trial

The Lancet Haematology - United Kingdom
doi 10.1016/s2352-3026(19)30014-6
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Elsevier BV

Related search

Phase 2 Trial of Ixazomib in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib

Blood Cancer Journal
OncologyHematology
2015English

Response-Adapted Intensification With Cyclophosphamide, Bortezomib, and Dexamethasone Versus No Intensification in Patients With Newly Diagnosed Multiple Myeloma (Myeloma XI): A Multicentre, Open-Label, Randomised, Phase 3 Trial

The Lancet Haematology
Hematology
2019English

Effects of a Self-Managed Home-Based Walking Intervention on Psychosocial Health Outcomes for Breast Cancer Patients Receiving Chemotherapy: A Randomised Controlled Trial

Supportive Care in Cancer
Oncology
2015English

Leptotrichia Bacteremia in Patients Receiving High-Dose Chemotherapy

Journal of Clinical Microbiology
Microbiology
2011English

Phenytoin for Neuroprotection in Patients With Acute Optic Neuritis: A Randomised, Placebo-Controlled, Phase 2 Trial

The Lancet Neurology
Neurology
2016English

Nadroparin or Fondaparinux Versus No Thromboprophylaxis in Patients Immobilised in a Below-Knee Plaster Cast (PROTECT): A Randomised Controlled Trial

Injury
SurgeryOrthopedicsSports MedicineEmergency Medicine
2017English

Pomalidomide Plus Low-Dose Dexamethasone Versus High-Dose Dexamethasone Alone for Patients With Relapsed and Refractory Multiple Myeloma (MM-003): A Randomised, Open-Label, Phase 3 Trial

The Lancet Oncology
Oncology
2013English

Furosemide Versus Mannitol in Japanese Patients With Thoracic Malignancy Who Received Cisplatin-Based Chemotherapy Using Short Hydration: Study Protocol for a Randomised Controlled Trial

BMJ Open
Medicine
2019English

Phase II Study of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

British Journal of Haematology
Hematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy